Molecular Partners AG
SIX:MOLN

Watchlist Manager
Molecular Partners AG Logo
Molecular Partners AG
SIX:MOLN
Watchlist
Price: 4.85 CHF 0.73% Market Closed
Market Cap: 178.8m CHF
Have any thoughts about
Molecular Partners AG?
Write Note

Molecular Partners AG
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Molecular Partners AG
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Molecular Partners AG
SIX:MOLN
Capital Expenditures
-CHf794k
CAGR 3-Years
6%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Capital Expenditures
-$3.2m
CAGR 3-Years
-5%
CAGR 5-Years
-5%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
Capital Expenditures
-CHf652k
CAGR 3-Years
38%
CAGR 5-Years
16%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Capital Expenditures
-$2.4m
CAGR 3-Years
69%
CAGR 5-Years
18%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Capital Expenditures
-CHf1.2m
CAGR 3-Years
12%
CAGR 5-Years
-15%
CAGR 10-Years
2%
Kuros Biosciences AG
SIX:KURN
Capital Expenditures
-CHf849k
CAGR 3-Years
-45%
CAGR 5-Years
-56%
CAGR 10-Years
N/A
No Stocks Found

Molecular Partners AG
Glance View

Market Cap
178.8m CHF
Industry
Biotechnology

Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

MOLN Intrinsic Value
3.07 CHF
Overvaluation 37%
Intrinsic Value
Price

See Also

What is Molecular Partners AG's Capital Expenditures?
Capital Expenditures
-794k CHF

Based on the financial report for Jun 30, 2024, Molecular Partners AG's Capital Expenditures amounts to -794k CHF.

What is Molecular Partners AG's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-1%

Over the last year, the Capital Expenditures growth was 35%. The average annual Capital Expenditures growth rates for Molecular Partners AG have been 6% over the past three years , -1% over the past five years .

Back to Top